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Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain pro-
tein, and LRRK2 mutants are recognized risk factors for Parkinson’s
disease (PD). Although the precise mechanisms that control LRRK2
regulation and function are unclear, the importance of the kinase
domain is strongly implicated, since 2 of the 5 most common fa-
milial LRRK2 mutations (G2019S and I2020T) are localized to the
conserved DFGψmotif in the kinase core, and kinase inhibitors are
under development. Combining the concept of regulatory (R) and
catalytic (C) spines with kinetic and cell-based assays, we discov-
ered a major regulatory mechanism embedded within the kinase
domain and show that the DFG motif serves as a conformational
switch that drives LRRK2 activation. LRRK2 is quite unusual in that
the highly conserved Phe in the DFGψ motif, which is 1 of the 4
R-spine residues, is replaced with tyrosine (DY2018GI). A Y2018F mu-
tation creates a hyperactive phenotype similar to the familial mu-
tation G2019S. The hydroxyl moiety of Y2018 thus serves as a
“brake” that stabilizes an inactive conformation; simply removing it
destroys a key hydrogen-bonding node. Y2018F, like the pathogenic
mutant I2020T, spontaneously forms LRRK2-decorated microtubules
in cells, while the wild type and G2019S require kinase inhibitors to
form filaments. We also explored 3 different mechanisms that create
kinase-dead pseudokinases, including D2017A, which further empha-
sizes the highly synergistic role of key hydrophobic and hydrophilic/
charged residues in the assembly of active LRRK2. We thus hypothe-
size that LRRK2 harbors a classical protein kinase switch mechanism
that drives the dynamic activation of full-length LRRK2.
kinase architecture | LRRK2 | Parkinson’s disease | DFG motif |
Leucine-rich repeat kinase 2
Parkinson’s disease (PD) is one of the most prevalent neuro-degenerative diseases, and proper treatment is not available
due in large part to our poor understanding and contradictory
data regarding the underlying pathogenic mechanism (1–3). One
gene product identified in PD pathogenicity is the Leucine-rich
repeat kinase 2 (LRRK2) encoded on the PARK8 gene.
LRRK2 is a large multidomain protein (Fig. 1A) that contains
several mutations that are known to be important risk factors for
familial PD (4–7). Although cross-talk between GTPase domains
and kinase domains are frequent in biology, LRRK2 is one of the
few examples in the human kinome where both domains are
embedded in the same polypeptide chain (8, 9). While the pre-
cise mechanism for LRRK2 activation and function is still being
explored, it is thought that LRRK2 exists in several different
conformational states. In the cytoplasm, it is predicted to be an
inactive monomer, while an active dimer/multimer is present at
membranes (10, 11). In addition, 3 of the 5 most common
pathological, familial mutants of LRRK2 (R1441C, Y1699C,
I2020T) are predicted to form filamentous structures that rep-
resent LRRK2 docked onto microtubules (12). Until now, it is
not clear if the docking onto microtubules is associated with the
pathogenicity of those mutations. However, these results indicate
that conformational flexibility is thus an intrinsic feature of
LRRK2. LRRK2 is also a protein kinase A (PKA) substrate, and
phosphorylation promotes docking of LRRK2 onto 14-3-3 pro-
teins (13–17). Finally, Rab proteins are known substrates of
LRRK2 (18–22). LRRK2 thus has many docking partners and
interfaces. Our goal here is to explore how the conformational
dynamics of the kinase domain contribute to the overall con-
formational dynamics of full-length LRRK2.
The kinase core of LRRK2 is depicted in Fig. 1 and SI Ap-
pendix, Fig. S1. In summary, there are 2 hydrophobic “spines”
that define the core architecture of every eukaryotic protein ki-
nase (23–25). The first to be recognized was the regulatory (R)
spine that is assembled in every active kinase but typically broken
in inactive kinases (23, 25). Protein kinases, like G proteins, are
dynamic molecular switches, and the essential elements for ac-
tivating the switch mechanism are embedded in the assembly of
the R-spine (23). In addition, there is a catalytic (C) spine that is
completed by the adenine ring of adenosine triphosphate (ATP),
and occupancy of this pocket synergizes the kinase for transfer of
the phosphate (24). The R-spine (RS) and C-spine (CS) residues
of LRRK2 as well as the positions of the 2 familial kinase domain
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mutations, G2019S and I2020T, are summarized in Fig. 1 B andD,
and the nomenclature for the spine residues is in Table 1 and SI
Appendix, Fig. S1.
To describe the core architecture of the kinase domain of
LRRK2, we used BRAF and PKA as model systems. Our pre-
vious studies with BRAF (26–28) as well as subsequent NMR
studies with PKA (29) validated the hypotheses that the C-spine
and R-spine are critically important for catalysis and activation,
respectively, and established these spines as key conserved fea-
tures of protein kinase core architecture. The numbering of the
corresponding residues in BRAF, PKA, and LRRK2 is included
in Table 1. A481 in BRAF (A1904 in LRRK2; CS8) is a highly
conserved C-spine residue that lies on top of the adenine ring.
When mutated to Phe in BRAF (A1904F), ATP binding is
abolished, presumably because the phenyl ring occupies the ad-
enine binding pocket (26, 28). Although this mutant has the
phenotype of a dead pseudokinase, it can, nevertheless, still bind
to wild-type (wt) BRAF and/or CRAF and serve as an activator
(28). Mutation of the R-spine residue L505F (RS3; L1924F in
LRRK2) and the flanking residue L485F (F1908 in LRRK2) to
increase hydrophobicity led to constitutive activation of BRAF
(26, 27). Since LRRK2 lies on the same branch of the kinome
tree and is a close homolog of BRAF, we used these 2 strategies,
fusing the C-spine and altering the hydrophobicity of the
R-spine, to test the importance of the R- and C-spine residues of
LRRK2 for activation and conformational transitions. We used
3 different kinase assays (autophosphorylation, phosphorylation
of a peptide substrate [LRRKtide], and phosphorylation of
2 different proteins [Moesin and Rab8a]). In addition, cell-based
assays were used to test the effect of all mutations on protein
redistribution and filament formation (12).
Using A1904F (CS8) as a prototype for a C-spine fusing mu-
tant and multiple mutations of R-spine and R-spine flanking
residues, we explored the hydrophobic space of the kinase core
Fig. 1. Identification of kinase spines in LRRK2. (A) Domain composition of LRRK2 highlighting the kinase domain as a central hub for LRRK2 regulation. (B)
Spine residues in LRRK2 were identified based on a structural model of SRC1. The C-spine (CS1 to CS8) and the R-spine (RS1 to RS4) are connecting the N lobe
(light gray) and the C lobe (dark green) and are bridged via the αF helix (red). The C-spine can only be completed by the recruitment of ATP (Left). (C and D)
The magnesium-positioning loop contains the DYGψmotif, which encompasses 2 of the most common PD-related mutations (G2019S and I2020T). This loop is
a hotspot for disease mutations, with D2017 being essential for orientating the γ-phosphoryl of ATP in most protein kinases. (E) The R-spine connects several
highly conserved motifs in the kinase core. RS1 is part of the catalytic loop, including the HRD motif (YRD in LRRK2), while RS2 is an anchor of the AL. RS3 is
orientating the αC helix. The highly flexible DYG motif as well as the αC helix are stabilized by R-spine formation via hydrophobic interactions between RS2,
RS3, and RS1, with RS4 belonging to the β-strand 4 of the N lobe.
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domain of LRRK2. In addition, we investigated the motifs that
anchor the R-spine residues within the kinase core (Fig. 1E).
Three conserved kinase motifs (the His Arg Asp [HRD] motif,
the DFGψ motif [where ψ is a hydrophobic amino acid], and the
αC helix) are critically important for ATP and substrate orien-
tation as well as to prime the kinase for phosphoryl transfer. The
HRD motif includes RS1 and is anchored to the catalytic loop,
the DFGψ motif includes RS2 and is anchored to the Mg posi-
tioning loop, and the αC helix includes the E1920 motif and RS3,
while RS4 is embedded in the β4 strand. The C-spine residue
A1904 is anchored in β3 (CS8). The RS2 site was of particular
interest, because 2 of the common familial mutations are located
in this motif. By mutating each of the DFGψ motif residues, we
discovered that the Y2018 is critical for stabilizing the inactive
conformation of LRRK2. Although this residue is conserved as a
Phe in most other kinases, in LRRK2, it is a Tyr. Mutating
Y2018 to Phe created a hyperactive form of LRRK2, similar to
but even more active than the familial G2019S mutant. The
hydroxyl moiety of Y2018 thus serves as a “brake” that stabi-
lizes an inactive conformation; simply removing it destroys a
key hydrogen-bonding node. The DFGψ motif is the most
highly mutated region in the cancer kinome (30), and we de-
lineate here the unique features of each residue in this motif.
Our results suggest furthermore that destabilizing the inactive
state of this motif is what drives the pathogenic mutations in
this region. Both Y2018 and I2020 are critical for locking
LRRK2 into an inactive state. Here, we define the presumed
docking sites for these 2 residues, one most likely driven by
hydrogen bonding and the other driven by hydrophobicity, as
essential for stabilizing the inactive conformation of LRRK2.
Results
Identification of Spine Residues in the Kinase Core of LRRK2. Hy-
drophobic spines are critical hubs in the core of every kinase. In
addition to their role in orienting residues for the catalytic step
(i.e., phosphoryl transfer), formation of these spines is also in-
volved in essential ways in noncatalytic, regulatory functions,
such as dimerization, and for overall activation. The switch
mechanism that converts an inactive kinase into an active kinase,
for example, is thought to be embedded in the conformational
changes that are correlated with assembly of the R-spine (25,
31). To test the role of the spines in LRRK2 activity and regulation,
we first identified the spine residues using a structure-based
alignment of all kinases in the ProKinO database (31–34). This
led to a computational model of the active conformation of the
kinase domain of LRRK2, where all spine residues are identified
(Table 1 and SI Appendix, Fig. S1). For our computational
modeling, we used Phyre2 (http://www.sbg.bio.ic.ac.uk/∼phyre2)
and based the calculations on the protooncogene tyrosine-
protein kinase SRC (35). A model based on BRAF gave simi-
lar results. Our model and the assignments of the spine residues
are also consistent with the previous LRRK2 model proposed
by Guaitoli et al. (36). Although we recognize that the N- and
C-linker regions that flank the kinase domain are critically im-
portant for function, our calculations were restricted solely to the
kinase domain (residues 1851 to 2135). Our model of the kinase
domain with C and R spines assembled reflects the active con-
formation of the kinase domain. Most spine residues are con-
served between LRRK2, PKA, and BRAF (Table 1). In
particular, the C-spine residues surrounding the adenine binding
pocket (CS6 to CS8) as well as the R-spine residues RS1, RS3,
and RS4 are identical in PKA and LRRK2. Notably, the F185
(RS2) residue within the DFGψ motif of PKA and almost all
other eukaryotic protein kinases (EPKs) is changed to a Tyr
(Y2018) in LRRK2. Only a few other kinases in the human
kinome (e.g., LRRK1, NEK9, and VRK1/2) have a Tyr at this
position.
Mutation of C-Spine Residues.Having identified the spine residues
in the LRRK2 kinase core, we first sought to lock the kinase into
an active-like yet catalytically inert conformation based on our
earlier studies with BRAF (28). By replacing the highly con-
served adenine capping residue, A1904 in β3, with Phe (Fig. 2A),
we hypothesized that the phenyl side chain would occupy the ad-
enine binding pocket and thereby, complete the C-spine. Thus, this
mutant should still assume an active-like conformation while being
unable to bind ATP; this mutant would be classified as a pseu-
dokinase. The A1904F mutation indeed abolished kinase activity
using LRRKtide (RLGRDKYKTLRQIRQ) as a peptide substrate
in a microfluidic mobility shift assay (Fig. 2C). Moesin and Rab8a
phosphorylation as well as autophosphorylation were dramatically
reduced (Figs. 2B and 3D). The constitutive phosphorylation of
Ser910, Ser935, and Ser955 was, however, unchanged (SI Appendix,
Fig. S2). V1893 (CS7) is another C-spine residue in the N lobe that
caps the adenine ring, and mutation of V1893F also abolished
kinase activity similar to A1904F and comparable with our earlier
results with BRAF (SI Appendix, Fig. S2).
Typically, mutations of the β3-Lys (K72 in PKA, K1906 in
LRRK2) in the regulatory triad (RT) (Fig. 2A) are done to
create kinase-dead mutants. Following this line, we compared
the activity of the A1904F (CS8F) mutant with K1906M
(RT1M). In addition, we mutated another key residue that is
critical for phosphotransfer, D2017A in the DYGψ/DFGψ
motif. This also created a kinase-dead phenotype (Fig. 2 B and
C). Thus, we have 3 different generic mechanisms for creating a
kinase-dead mutant. K1906M (RT1A/M) contributes to posi-
tioning of the α- and β-phosphates of ATP as well as opening
and closing of the active site cleft (37), D2017A controls the
binding of the second metal ion and the transfer of the
γ-phosphate, and A1904F sterically interferes with binding of
the adenine ring.
In addition to our kinetic assays of LRRK2 catalytic functions,
we utilized a cell-based assay to evaluate the capacity of
Table 1. Numbering and comparison of PKA, LRRK2, and BRAF
spine residues
Motif and numbering PKA LRRK2 BRAF
C-spine
CS8 A70 A1904 A481
CS7 V57 V1893 V471
ATP ATP ATP
CS6 L173 L2001 F583
CS5 I174 L2002 L584
CS4 L172 V2000 I582
CS3 M128 L1955 L537
CS2 L227 L2062 V645
CS1 M231 I2066 L649
R-spine
RS4 L106 L1935 F516
RS3 L95 L1924 L505
RS2 F185 Y2018 F595
RS1 Y164 Y1992 H574
“Shell”
Sh3 M118 L1945 I526
Sh2 M120 M1947 M528
Sh1 V104 I1933 L514
Regulatory triad
RT3 D185 D2017 D594
RT2 E91 E1920 E501
RT1 K72 K1906 K483
Hydrophobic network
HN1 L74 F1908 L485
Sh, shell residues.
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LRRK2 wild-type and mutant proteins to form filaments that
correlate with docking onto microtubules. We and others showed
previously that 3 of the 4 common familial mutants of LRRK2
dock spontaneously onto microtubules (12, 38–42). We, there-
fore, transfected HEK293T cells with LRRK2 A1904F and
evaluated LRRK2 localization. Overexpression of wt LRRK2
showed filament formation in only a small percentage of cells in
contrast to the pathogenic mutant I2020T, which showed fila-
ments in the majority of cells (Fig. 2D). Although A1904F re-
sembles the kinase-dead mutant in terms of activity, cells
expressing A1904F showed slightly more filamentous structures
than cells transfected with wt LRRK2 (Fig. 2D). Consistently,
both kinase-dead mutants D2017A and K1906M showed no
filament formation. These findings suggest that the formation
of spines and therefore, the conformational state of the kinase
domain may also be involved in noncatalytic functions, such as
cellular localization.
The DYGψ Motif Controls R-Spine Formation and Maintains LRRK2 in
an Attenuated State.While the C-spine is essential for positioning
the adenine ring of ATP and in turn, the phosphates for catalysis,
the R-spine is required for assembly of an active kinase. The
correlated motions of the αC helix and the DFGψ motif lead to
the assembly of the conserved regulatory triad (K1906, E1920,
and D2017) and in particular, the magnesium binding loop,
which correlates with positioning of the γ-phosphate (Fig. 2A). In
BRAF, the assembly of the R-spine is dynamically facilitated by
phosphorylation (activation loop [AL]) and/or dimerization. To
investigate the influence of R-spine assembly on kinase activity
as well as cellular localization, we increased the hydrophobicity
of all R-spine (RS1 to RS4) residues (Fig. 3A). These Phe mu-
tants Y1992F (RS1F), Y2018F (RS2F), L1924F (RS3F), and
L1935F (RS4F) were then assayed for autophosphorylation us-
ing γ-[32P]ATP. As shown in Fig. 3B, all R-spine mutants still
undergo autophosphorylation; however, RS1F, RS3F, and RS4F
show slightly reduced signals compared with the wt (SI Ap-
pendix, Fig. S7). In contrast, the DYGψ motif mutant RS2F
(Y2018F) displayed increased autophosphorylation, which was
also found for the hyperactive G2019S mutant. These findings
were also confirmed using a phospho-specific antibody against a
major autophosphorylation site, S1292 (Fig. 3C and SI Appen-
dix, Fig. S7A). The same pattern (increased phosphorylation for
RS2F [Y2018F] and decreased phosphorylation for RS1F,
RS3F, and RS4F) was also observed for pT1491 and pT1503
Fig. 2. The C-spine mutation A1904F is kinetically inert. (A) The regulatory triad (RT1 to RT3), defined by the interaction of K1906 (RT1, β-strand 3) with E1920
(RT2, αC helix) and D2017 (RT3, DYG motif), is essential for phosphoryl transfer by promoting the correct orientation of ATP. A1904 (CS8) is critical for
controlling ATP binding. Mutating any of these residues results in catalytically almost inactive kinases. (B) Auto- and substrate (Moesin) phosphorylation of
LRRK2 wt, K1906M, D2017A, and A1904F was tested in a radioactive kinase (γ-[32P]ATP) assay. A1904F (CS8) shows almost no kinase activity comparable with
the kinase-dead mutants, K1906M and D2017A. (C) Microfluidic mobility shift kinase assay with LRRKtide as a peptide substrate demonstrates no kinase
activity for kinase-dead and C-spine (CS8) mutants. (D) A filament formation assay was performed in HEK293T cells overexpressing LRRK2 constructs 48 h after
transfection. In contrast to wt, D2017A (DFGψ), and K1906M (RT1M), the C-spine mutant LRRK2 A1904F (CS8) causes filament formation in a subset of cells.
The frequency of cells bearing LRRK2 filaments was drastically increased in the pathogenic mutation I2020T (DFGψ). Data are means ± SD of 2 to 5 in-
dependent experiments.
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(Fig. 3C and SI Appendix, Fig. S7). Interestingly, enhanced
phosphorylation of pT2483 in the WD40 domain could be ob-
served only for G2019S but not for Y2018F. Another residue that is
part of the local hydrophobic environment around the DFGψmotif
is F1908, which is an Leu in PKA and BRAF. Replacing L485 by
Phe in BRAF created a constitutively active oncogene (26). The
parallel experiment in LRRK2, replacing the corresponding Phe
with Leu (F1908L), led to an ∼80% loss of activity (Table 2).
Substrate phosphorylation was next examined using a general
substrate of LRRK2, Moesin, in an in vitro kinase assay. These
data demonstrate again hyperactivity for Y2018F and G2019S.
In contrast, all other R-spine mutations reduced Moesin
phosphorylation (Fig. 3B). As a more physiological substrate of
LRRK2, we used recombinant Rab8a. Rab8a phosphorylation
was strongest for G2019S followed by I2020T and Y2018F,
which still displayed a slightly higher degree of Rab8a phos-
phorylation compared with wt LRRK2 (Fig. 3D and SI Ap-
pendix, Fig. S7E). Again, these results suggest an increased
kinase activity of Y2018F. In contrast to using Moesin as a
substrate, the Phe mutations of RS1 and RS3 did not alter
Fig. 3. In vitro kinase assays render the LRRK2 R-spine mutation Y2018F (RS2) hyperactive. (A) The R-spine of LRRK2 connects 2 of the most flexible motifs in
kinases, the αC helix via RS3 (L1924) and the AL (red) via RS2 (Y2018). (B) Based on kinase assays (Moesin) and autophosphorylation using [γ32P]-ATP, Y2018F
(RS2F) was identified as a hyperactive kinase variant beside G2019S. All other R-spine mutations showed less phosphorylation. (C) Increased autophosphorylation
was also revealed by Western blot analyses for Y2018F (RS2F) at positions S1292 and T1503 but not for T1491. G2019S, however, showed increased signals for
all tested autophosphorylation sites. Y1992F (RS1F), L1924F (RS3F), and L1935F (RS4F) showed reduced autophosphorylation. (D) Reduced kinase activity for
these mutants (Y1992F [RS1F], L1924F [RS3F], L1935F [RS4F]) was also found in an in vitro kinase assay with His-Rab8a (6-175). In contrast, Y2018F (RS2F),
G2019S, and I2020T showed slightly enhanced phosphorylation of T72 in Rab8a. Rab8a phosphorylation was negligible for A1904F (CS8F), D2017A (DYG), and
for the wt in the presence of 500 nM MLi-2. (E) Michaelis–Menten kinetics (raw data are in SI Appendix, Fig. S3 C and D) again demonstrate hyperactivity of
Y2018F based on LRRKtide phosphorylation in a mobility shift assay. (F and G) KM(ATP) and kcat values from Michaelis–Menten kinetics using LRRKtide as
substrate. All other tested spine mutations displayed reduced kinase activity.
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Rab8a phosphorylation, while RS4F again showed reduced
activity. In vivo, Rab29 has been shown to activate LRRK2
kinase activity; so, one has to be very cautious in evaluating
physiological substrates, as each substrate could also have ad-
ditional mutation-independent activating or inhibiting effects
(22). Therefore, it must be considered that these effects may
compensate for inhibiting or activating effects of LRRK2 mu-
tations or are even able to strengthen those.
To achieve quantitative kinetic data, we used the microfluidic
mobility shift kinase assays using peptide substrate LRRKtide.
For accurate determination of active kinase concentrations, we
established a titration assay utilizing the high-affinity LRRK2
inhibitor MLi-2 (43). This allowed us to determine specific
kinase activities independent of variations in enzyme expres-
sion and purification (SI Appendix, Fig. S3). We determined
accurate specific activities (kcat) for all catalytically active
LRRK2 mutants. Strikingly, based on the active concentration,
the RS2F mutant (Y2018F) seems to be even more active than
the hyperactive familial mutant G2019S (Fig. 3 E and F and
Table 2).
All other R-spine mutants showed decreased yet detectable
kinase activity (Fig. 3F and Table 2). Contrary to the Western
blot assay with Rab8a, the familial kinase mutation I2020T
resulted in lower kinase activity compared with LRRK2 wt.
Both higher and lower kinase activities have been reported
previously for I2020T depending on the assay and substrate
used (1, 2, 44–49), and our analysis here points out how critical
the choice of an assay can be. While small peptides allow us to
quantitively determine kinetic properties, conceptionally one
should appreciate that protein substrates are more physiologi-
cally relevant. We then determined the KM values for ATP for
all active mutants summarized in Table 2 (Fig. 3G). The
KM(ATP) values for G2019S, RS3F (L1924F), and RS1F
(Y1992F) were similar to wt LRRK2, while I2020T, RS4F
(L1935F), and RS2F (Y2018F) all showed a 2- to 3-fold reduced
KM(ATP). Having KM(ATP) and kcat allowed us to also determine
catalytic efficiency kcat/KM (Table 2). By these criteria, the Y2018F
mutant is significantly more catalytically efficient than either wt
LRRK2 or G2019S (Table 2).
Y2018F Overexpression Resembles the Phenotype of the Overexpressed
Pathogenic I2020T Mutant in a Cellular Context. All R-spine mutants
were probed in a cellular context for filament formation.
HEK293T cells were transiently transfected with the plasmids
coding for the respective full-length proteins and treated with
MLi-2 or dimethyl sulfoxide (DMSO) (control). In line with
previously reported results, wt LRRK2 as well as G2019S
showed a cytosolic distribution in the absence of the inhibitor
(12). Treatment with a specific LRRK2 inhibitor for 2 h (MLi-
2, 100 nM) induced filament formation of the wt and G2019S in
the majority of cells (approximately 80%) (Fig. 4).
Strikingly, the DYGψ motif mutant RS2F (Y2018F) showed
filament formation even in the absence of MLi-2, and treatment
with MLi-2, similar to I2020T, further enhanced the proportion
of cells exhibiting microtubule association (Fig. 4). Thus, the
conformation and/or flexibility of the Y2018F and I2020T mu-
tants in the absence of inhibitor are somehow different from wt
LRRK2 and G2019S. The Y2018F mutant also demonstrates
that filament formation does not correlate with increased kinase
activity. All other R-spine mutations showed robust filament
formation only in the presence of MLi-2. These results reinforce
the hypothesis that filament formation and microtubule associ-
ation are conformation-driven effects.
We also tested the kinase-dead mutants described above to see
if MLi-2 induced filament formation. The 2 kinase-dead muta-
tions K1906M (RT1M) and D2017A (DFGψ/RT3) consistently
showed no filaments independent of inhibitor treatment (Fig. 4
and SI Appendix, Fig. S4). Filament formation associated with
the C-spine mutant (A1904F) was also not enhanced by binding
of MLi-2, consistent with our hypothesis that the ATP site is
sterically blocked. Interestingly, the K1906A mutant showed a
slight increase in filament formation in the presence of MLi-2,
suggesting that the inhibitor can still bind to the nucleotide
site, even though the protein lacks catalytic activity. These
phenotypic differences in the ability of different mutants, in-
cluding the pathological mutants, to induce filament formation
and association with microtubules may provide important in-
sights for the design of kinase inhibitors that do not promote
this filamentous pattern.
PKA Model. To ask whether introducing a tyrosine into the
DFGψ motif in other kinases may lead to inhibition, we used
the PKA catalytic subunit as a model. Specifically, we mutated
F185 (Y2018 in LRRK2) to Tyr. In addition, we changed G186
(G2019 in LRRK2) to Ser and also, generated the double
mutant (F185Y/G186S). We expressed, purified, and assayed
the resulting mutants using the peptide substrate PKStide
(PKIα [14–22] A21S, GRTGRRNSI-NH2). As seen in SI Ap-
pendix, Fig. S5, the mutation F185Y did not have an inhibitory
effect on the C subunit as for LRRK2; instead, it was signifi-
cantly more active than the wt C subunit. The other 2 mutants
also show an increase in kinase activity. The results emphasize
that the switch mechanism is highly specific for each protein
kinase, and each kinase is sensitive to subtle changes in the
DFGψ motif.
Discussion
Protein kinases have evolved to be highly regulated molecular
switches that are precisely activated in response to specific bi-
ological cues. In LRRK2, the kinase domain is embedded in a large
multidomain protein, and much is still unknown about the biological
role of LRRK2 and how it is activated. Using a combination of
structure-based analysis and site-directed mutagenesis accompanied
with cell-based microtubule decoration assays, we discovered a
previously unappreciated regulatory mechanism for the LRRK2
kinase domain. Based on our studies of BRAF, a close LRRK2
homolog, we hypothesized that the dynamic switch mechanism for
activation of LRRK2 would be embedded in the kinase domain,
specifically in the conformational changes that lead to the as-
sembly of the hydrophobic R-spine (50). By exploring the role of
the R-spine residues and more specifically, the DYGψ motif, we
discovered that the DYGψ tyrosine is a key residue for controlling
the switch mechanism. Replacing Y2018 with Phe releases the
brake that holds the inactive conformation in place and leads to the
creation of a hyperactive kinase. In addition, we explored 3 different
mechanisms that create kinase-dead pseudokinases, which further
Table 2. Kinetic parameters of LRRK2 constructs
LRRK2 construct KM(ATP), μM kcat, 1/min kcat/KM, 1/(min μM)
wt 136 ± 23 140 ± 32 1.1 ± 0.3
A1904F (CS8) — Inactive —
L1924F (RS3) 113 ± 18 40 ± 6 0.36 ± 0.06
L1935F (RS4) 76 ± 22 14 ± 12 0.10 ± 0.04
Y1992F (RS1) 204 ± 25 45 ± 9 0.23 ± 0.06
D2017A (DFGψ) — Inactive —
Y2018F (RS2/DYGψ) 85 ± 12 413 ± 40 4.9 ± 0.9
G2019S (DFGψ) 138 ± 15 322 ± 35 2.4 ± 0.2
I2020T (DFGψ) 43 ± 18 79 ± 12 2.3 ± 1.5
F1908L (HN1) 85 ± 9 17.4 ± 0.8 0.21 ± 0.02
Values are given as mean ± SD from at least 2 independent protein prep-
arations with each preparation measured at least twice except for F1908L,
where 1 protein preparation was measured in 4 independent experiments.
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emphasize the synergistic role of hydrophobic and hydrophilic/
charged residues in the activation of LRRK2 and of all active kinases.
The importance of the DFGψ motif and the R-spine is further
emphasized by the fact that 2 of the PD risk factor mutations in
LRRK2, G2019S, and I2020T are localized within this motif.
This information plus our analysis allow us to better appreciate
the detailed features of this finely tuned mechanism. The prin-
ciples also build on our previous analysis of BRAF, where we
initially validated the importance of the spine hypotheses (26).
The DFGψ motif is indeed a “hot spot” for mutations in cancer-
associated kinase oncogenes (30), and therefore, we anticipate
that there will be many other examples where simply releasing
the brake (in this case, a simple hydroxyl group) may be suffi-
cient to create an oncogene.
To appreciate the implications of the Y2018F mutation, it is
useful to look more closely at the integration of the R-spine and
the DFGψ motif. The R-spine is composed of 4 residues, and
each is linked to a conserved functional motif (Fig. 1E). RS1 is
firmly anchored to the catalytic loop in the C lobe, while RS4 is
anchored to β4 in the N lobe. In contrast, the intervening R-spine
residues RS2, embedded in the DFGψ motif, and RS3, anchored
to the αC helix, are highly dynamic. The correlated motions of the
DFGψmotif and the αC helix lead to the assembly of the essential
regulatory triad at the active site cleft (Fig. 2A), which allows for
the precise orientation of the γ-phosphate so that it is poised for
transfer to a protein substrate (25). Each residue in the DFGψ has
a specific role to play. The Asp (D2017) is the residue that must
be precisely positioned at the active site to allow for the transfer
of the γ-phosphate (Fig. 5A). In most kinases, the second res-
idue is a Phe, which provides a flexible hydrophobic driving
force or “grease” for the assembly of the R-spine. While Y2018
in LRRK2 also provides hydrophobicity, there is an important
difference. It also has a hydroxyl moiety, which can provide
additional interactions that precisely regulate the positioning of
the side chain. Replacing the Y2018 with Phe retains the hy-
drophobicity but abolishes the precise positioning that is me-
diated by the hydroxyl moiety, and this leads to an unleashed
kinase. A stabilized “OFF” state for Y2018 presumably favors a
disassembled, inactive R-spine conformation (Fig. 5A), and
identifying the pocket that provides the hydrogen bond donor
and/or acceptor will be an important future challenge. G2019S,
the most common risk factor mutation, is also hyperactive but
most likely for different reasons. The conserved glycine in this
motif is almost certainly there to provide a highly flexible hinge
to mediate the transition from active to inactive. The equilib-
rium in most kinases will favor the inactive conformation. The
transition from active to inactive is slowed down, and in
LRRK2, the simple replacement of the Gly with Ser favors the
active conformation (51). In most kinases, the ψ residue,
I2020 in LRRK2, is hydrophobic. This residue has a role in
shielding the active site from water in the active conformation
and may also contribute to recognition of the P + 1 residue in
the protein/peptide substrate (52). We predict that there is also
a hydrophobic pocket in full-length LRRK2 that contributes to
stabilization of the OFF state (Fig. 5A). A structure of full-
length LRRK2 will be needed to identify this pocket.
Enhancing the hydrophobicity of the spine residues and their
neighboring environment is another strategy that was exempli-
fied by the BRAF mutants (27, 28). In the case of LRRK2, we
find that increasing the hydrophobicity of the other spine resi-
dues actually led to a reduction in activity, although we did not
further explore the mechanism. We emphasize that the hydro-
phobic space of each kinase must be carefully examined. Most of
the hydrophobic residues in the R-spine and the surrounding
residues are conserved in PKA, BRAF, and LRRK2 with 1 ex-
ception. Residue 1908 in β3 is a Phe in LRRK2 but an Leu in
Fig. 4. Filament formation is increased for Y2018F (RS2) and I2020T. (A) HEK293T cells were transfected with 1 μg of Flag-tagged LRRK2 DNA and stained
with an Alexa568-tagged antibody combination against Flag. Microtubule association was defined by rod-like filamentous structures with increased
fluorescence intensity, while a homogenous fluorescence distribution is considered to represent cytosolic localization of LRRK2. Representative images are
shown for each variant in the absence and presence of 100 nM MLi-2. While the kinase -dead mutants (e.g., D2017A) are cytosolically distributed in the
presence of MLi-2, most constructs display filament formation within 60 to 80% of the transfected cells. In the absence of inhibitor, all LRRK2 constructs are
cytosolically distributed except Y2018F and I2020T, which show a filamentous pattern of expression in 50 to 60% of the transfected cells. (B) Percentages of
cells exhibiting LRRK2 filament formation. Data are means ± SD of 2 to 5 independent experiments. Each transfected construct was measured at least twice
in the absence (−) and in the presence (+) of 100 nM MLi-2.
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PKA in BRAF. Mutating this residue to Phe in BRAF is an
oncogenic mutation that enhances the hydrophobic contacts
between β3 and the αC helix (26). This is consistent with our
finding that approximately 80% of the LRRK2 kinase activity is
lost when F1908 is replaced with Leu. We suggest that F1908
may contribute to the strong activating phenotype of the Y2018F
mutant. After the brake mechanism associated with the Tyr hy-
droxyl moiety is broken, LRRK2 is poised to be stabilized in an
active conformation. In general, the hydrophobic environment
around the spine residues in LRRK2 is more extensive than in
PKA and BRAF, which may also contribute to the strong acti-
vating phenotype of Y2018F. Once again, we emphasize that the
hydrophobic space of the core is kinase specific; each kinase
must be analyzed individually.
Assembly of the Regulatory Triad. The assembly of the hydrophilic
regulatory triad at the active site cleft is a direct and synergistic
consequence of the hydrophobic-driven assembly of the R-spine
(25). What do these 3 residues do, and why are they so important?
The Lys (K1906 in LRRK2) is anchored to the β-sheet, which is
rigid. It provides a “lighthouse beacon” to guide the positioning of
the Glu (E1920 in LRRK2) in the αC helix and anchors the α- and
β-phosphates of ATP. The Glu integrates the αC helix with the
β-sheet, creating a functional N lobe that is anchored to the AL (53).
This pair also coordinates opening and closing of the cleft
during the catalytic cycle (37). The Asp (D2016 in LRRK2) in
the DFGψ motif binds to the second metal ion and the
γ-phosphate of ATP. This Mg ion is the critical “linchpin” that
is essential for catalysis and for release of ADP (54, 55). Most
kinase crystal structures do not have an ordered γ-phosphate and
do not have the second metal ion. Here, we confirm the inactivating
consequences of K1906 and D2017 mutations. Our biggest chal-
lenge now is to elucidate the inactive conformation of wt full-length
LRRK2 where the regulatory triad is broken. As seen in SI Ap-
pendix, Fig. S6, we have no template for this, and the conformation
of most inactive kinases is not known, because the adjacent regu-
latory domains are deleted.
Activation Loops. We and others have modeled the active con-
formation of LRRK2 based on the structure of SRC and many
other kinases. BRAF is a good model for comparison, as
LRRK2 belongs to the same branch of the kinome tree. Al-
though much smaller, BRAF also provides a good model for how
an N-terminal domain (NTD) can reach over and stabilize the
inactive state, even though we do not yet have a structure of full-
length BRAF. As with most kinases, the terminal inhibitory
domain of BRAF is typically cleaved off to obtain a crystal
structure of the kinase domain bound to inhibitors. The NTD in
BRAF is predicted to reach over and cover the active site cleft
precisely in the region where the N and C lobes come together.
This is the home of the AL, and while we have many structures
now of ALs in active or semiactive conformations, in most in-
active kinases the AL is disordered, suggesting that ordering is
imposed by domains and/or motifs that lie outside the kinase
domain (SI Appendix, Fig. S6). There are a few cases, such as
SRC, where the AL is ordered very differently in the inactive
state, and here, we can see how the same residues that are es-
sential for the active conformation can play different roles in
stabilizing the inactive conformation. The E91PKA (RT2) equiva-
lent in the αC of inactive SRC, for example, is interacting with
the DFGψ + 2 Arg that will be part of the AL network when the
AL-Tyr is phosphorylated. In LRRK2, we predict that this resi-
due will be contributing to the active conformation of the AL as
it does in every other protein kinase. However, we also predict
that this region will likely be contributing to stabilizing the in-
active conformation of full-length LRRK2. Specifically, based on
cross-linking of the full-length inactive LRRK2 (36), K2030 in
the AL is a key residue for cross-linking to different parts of the
protein (Fig. 5B). Two major links are to the LRR domain
(K1249 and K1316), and 1 is to the Ankyrin repeats (K831).
There are also 2 cross-links within the kinase domain (K1910 and
Fig. 5. The kinase domain of LRRK2 is a critical hub for internal domain organization with an essential role of the R-spine to control function and activity. (A)
The assembly of the R-spine needs to be tightly regulated to control the conformation of the DYGψ motif and thereby, the ON and OFF states of the kinase.
Pathogenic mutations in this motif (i.e., G2019S [DYGψ] and I2020T [DYGψ]) alter kinase regulation and become a driving force for PD. With Y2018F (RS2/
DYGψ), we describe a mutation resembling features of both pathogenic mutations (i.e., hyperactive as G2019S and prone to form filamentous structures, like
I2020T). Both effects seem to be promoted by an active kinase conformation. For Y2018F, this might be driven by a loss of hydrophilic interactions in the DYG-
out conformation, while in the case of G2019S, the Ser reduces the flexibility of the Mg-positioning loop and stabilizes the ON state. For I2020T, we hy-
pothesize that a hydrophobic interaction in the DYG-out conformation with a not yet defined hydrophobic pocket is lost. (B) Cross-linking experiments (cross-
links are shown as red and black lines) by Guaitoli et al. (36) revealed several links of the kinase domain with other domains of LRRK2, such as the ANK and
LRR domain. Especially K2030 (red lines) and thereby, the AL seem to be localized to important domain interfaces in full-length LRRK2 as well as key
phosphorylation sites (yellow dots). (C) Sequence comparison of the AL and the P + 1 loop of LRRK2 and PKA. The AL harbors 2 adjacent cysteines, which may
be important for oxidation sensing.
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K2065). While the details of these cross-links need to be vali-
dated, they nevertheless suggest that the AL loop will be local-
ized to important domain interfaces in the full-length kinase that
will likely include the LRR and ankyrin repeats. This further
supports the model that the N-terminal region of LRRK2 will be
shielding the active site of the kinase domain in full-length
LRRK2 as we have already proposed earlier (13). Two adja-
cent Cys residues are another intriguing feature of the LRRK2
AL, and these might be sensitive to oxidation (Fig. 5C). Other
than providing hypotheses for the development of potent in-
hibitors, identifying the docking sites for Y2018 and I2020 is an
important future challenge to further understand the mechanism
of LRRK2 activation as well as how pathogenic mutations hijack
this process. Our analysis of LRRK2 also provides a general
strategy for analyzing the conformational dynamics of any un-
known protein kinase, even very large ones such as LRRK2.
Methods
Cell Culture and Transfection. LRRK2 wt and mutants were expressed with an
N-terminal Flag-Strep-Strep tag in HEK293T cells. For this, 1.0 × 107 cells
were seeded on 15-cm Ø cell culture dishes followed by a 24-h incubation
at 37 °C and 5% CO2 in Dulbecco’s modified eagle medium (DMEM) high
glucose (with L-glutamine; without sodium pyruvate; Biowest) supple-
mented with 10% fetal bovine serum (FBS). Subsequently, cells were
transfected with 15 μg per dish plasmid DNA (pCDNA3.0-FSS-LRRK2;
NM_198578), which was incubated for 30 min with 150 μL per dish poly-
ethylenimine in 1.5 mL DMEM high glucose and then added to each dish.
After 24 h, the medium was exchanged with fresh DMEM (high glucose,
+10% FBS), and cells were incubated for another 24 h before harvesting.
Cell pellets were stored at −20 °C before use.
Purification of Flag-Strep-Strep–Tagged LRRK2 Constructs. Cell pellets were
lysed in fresh, ice cold lysis buffer (25 mM Tris·HCl, pH 7.5, 150 mM NaCl,
10 mM MgCl2, 0.5% Tween 20, 500 μM guanosine diphosphate (GDP),
cOmplete ethylenediaminetetraacetic acid (EDTA) free protease inhibitor
mixture [Roche], PhosSTOP [Roche]) followed by a 30-min incubation at 4 °C.
Cell debris was removed by centrifugation at 42,000 × g and 4 °C for
40 min. After filtration (0.45-μm sterile filter), the supernatant was trans-
ferred on a Streptactin Superflow column (0.5 mL bed volume; IBA
Goettingen). Streptactin affinity purification was in principle performed
according to the manufacturer’s protocol, except that all buffers were
supplemented with 500 μM GDP (Biolog Life Science Institute) and 10 mM
MgCl2. Eluted protein LRRK2 was supplemented with 10% glycerol and
0.5 mM Tris(2-carboxyethyl)phosphine (TCEP) and stored at −80 °C. Con-
centrations were determined using the Bradford Protein Assay (56). Buffers
used for LRRK2 purifications were used for autophosphorylation and Moesin
phosphorylation assays, except that no additional MgCl2 was added.
Radioactive Phosphorylation Assays. Autophosphorylation of LRRK2 variants
was analyzed using [γ32P]-ATP. For this, Kinase Buffer (Cell Signaling) was
supplemented with 500 μM guanosine triphosphate (GTP), 100 μM ATP,
and 17 nM (≡1 μCi/37 kBq) [γ32P]-ATP. Each reaction was started by addition of
200 ng LRRK2 (wt or mutant). The reaction mix was incubated for 1.5 h at 30 °C.
The reaction was stopped by addition of NuPAGE sample buffer (Thermo
Fisher Scientific) and by incubation at 95 °C for 2 min. Samples were sepa-
rated using a NuPAGE Gel (4 to 12%) and stained with Coomassie brilliant
blue G for documentation. The gel was then incubated in a solution of 5%
glycerol and 20% EtOH followed by an overnight drying step while pinched
between 2 layers of cellophane. Radioactive autophosphorylation was de-
tected by photo film (24-h exposure at −80 °C).
Substrate phosphorylation was analyzed similarly, except that the reaction
was supplemented with 480 μg/mL GST-Moesin.
Autophosphorylation Analysis with Phospho-Specific Antibodies. LRRK2 spine
variants were tested for (auto-)phosphorylation with phospho-specific an-
tibodies from rabbit: pS910 (Epitomics #5098–1), pS935 (Epitomics #5099–1),
pS955 (Abcam MJF-R11 [75-1]), pS1292 (Abcam MJF 19–7-8), pT1491 (Abcam
MJF-R5 [88-3]), pT1503 (AbcamMJF-R6 [227-1a]), and pT2483 (AbcamMJF-R8
[21-2e]). For this, 200 ng LRRK2 was incubated in Kinase Buffer (Cell Sig-
naling) supplemented with 500 μM GTP and 100 μM ATP for 1.5 h at 30 °C.
After sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/
PAGE) and blotting, the respective nitrocellulose membrane was blocked
with TBS-T (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% [vol/vol] Tween-20)
containing 5% (wt/vol) bovine serum albumin (BSA) and was subsequently
incubated overnight with primary antibodies diluted in TBS-T (1:1,000).
Total LRRK2 was detected using an anti-Flag antibody (1:1,000, clone M2,
mouse; Sigma-Aldrich). Fluorescently labeled secondary antibodies (anti-
rabbit IRDye800CW and anti-mouse IRDye680RD, 1:15,000; LiCOR) were
used for the parallel detection of phospho-specific and anti-Flag using an
Odyssey FC imaging system (LiCOR).
Western Blot of Rab8a Phosphorylation by LRRK2 Spine Mutations and Pathogenic
Variants. Rab8a phosphorylation by LRRK2 was tested using a phospho-specific
antibody against phospho-Thr72 of Rab8a. Therefore, kinase assays containing
5 μM (6xHis)-Rab8a (6-175), 100 nM respective LRRK2 mutant, 25 mM Tris·HCl,
pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1 mM ATP, 0.5 mM GTP, 0.1 mg/mL BSA,
and 1 mM dithiothreitol (DTT) were performed at 30 °C for 30 min. Reactions
were stopped by adding sample buffer and denaturing the samples at
105 °C for 5 min. Samples were separated via SDS/PAGE and blotted onto
a nitrocellulose membrane. Subsequently, the membrane was blocked
with 5% (wt/vol) BSA in TBS-T for 1 h. Primary antibody incubation was
performed overnight at 4 °C with the phospho-specific anti-Rab8a
(phospho-T72) antibody (MJF-R20, rabbit; abcam) and an anti-His anti-
body (mouse; GE Healthcare). After secondary antibody incubation (anti-
rabbit IRDye800 and anti-mouse IRDye680, 1:15,000; LiCOR) for 1 h at room
temperature, signals were detected with the Odyssey FC imaging system
(LiCOR). FSS-LRRK2 wt and mutants were detected on an additional blot
using an anti-Flag antibody (1:1,000, clone M2, mouse; Sigma-Aldrich)
in combination with an anti-mouse antibody (anti-mouse IRDye680RD,
1:15,000; LiCOR).
Microfluidic Mobility Shift Kinase Assay. Michaelis–Menten kinetics of
LRRK2 for ATP were determined via a microfluidic mobility shift assay
combined with kinase assays using LRRKtide (RLGRDKYKTLRQIRQ-amide;
GeneCust) as a substrate. Microfluidic mobility shift kinase assays were
performed using assay buffer (25 mM Tris·HCl, 50 mM NaCl, 1 mM DTT,
0.5 mg/mL BSA) containing 950 μM LRRKtide and 50 μM fluorescein-
LRRKtide (LRRKtide solution), 50 nM LRRK2, 10 mM MgCl2, 0.5 mM GTP,
and the respective ATP dilution. Each reaction was started by adding the
LRRKtide solution to 384-well plates. A LabChip EZ Reader (PerkinElmer,
Inc.) was used to monitor substrate conversion for 1 h at 30 °C. The per-
cental conversion was plotted against time, and the slope (m = percentage
per minute) was determined using a linear fit. Subsequently, the slopes
were converted into reaction velocities (v0 = micromoles per minute), and
plotted against the respective ATP concentration, and KM as well as vmax
values were determined using a Michaelis–Menten fit. Measurements
were performed in triplicates with at least 2 independent protein
preparations.
The kinase assay was also used to determine active protein concentra-
tions by titrating each LRRK2 preparation with the high-affinity inhibitor
MLi-2 (Merck). Therefore, 24 μL of Buffer A (25 mM Tris·HCl, 50 mM NaCl,
1 mM DTT, 0.5 mg/mL BSA, 104.2 nM LRRK2) was mixed with 1 μL of an
MLi-2 dilution series (50× concentrated), which was prepared in 100%
DMSO. Subsequently, 10 μL of this reaction mix was added to 10 μL of
Buffer B (25 mM Tris·HCl, 50 mM NaCl, 1 mM DTT, 0.5 mg/mL BSA,
1,900 μM LRRKtide, 100 μM fluorescein-LRRKtide) containing x μM ATP (x =
KM[ATP] of the respective LRRK2 mutant). Substrate conversion was
monitored as described above, and resulting conversion rates were plot-
ted against the respective MLi-2 concentrations. Active protein concen-
trations were obtained by determining a linear fit (assuming an 1:1
binding of MLi-2).
Immunofluorescence and Laser Confocal Imaging. HEK293T cells were seeded
onto 6-well dishes containing poly-D-lysine–coated glass coverslips or onto
poly-D-lysine–coated glass-bottom dishes (MatTek Corporation). Cells were
transfected with the Lipofectamine 2000 reagent (ThermoFisher Scientific)
per the manufacturer’s protocol using 1 μg of tagged LRRK2 DNA. Trans-
fected cells grew for 48 h. They were then treated with the LRRK2 inhibitor
MLi-2 for 2 h before fixation with 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 15 min at room temperature. Cells were
washed in PBS, permeabilized in 0.1% Triton X-100, and blocked in 1%
BSA, 50 mM glycine, and 2% normal serum. The primary rabbit anti-Flag
antibody (catalog no. PAB0900; Abnova Company) was mixed at a di-
lution of 1:250 in blocking buffer diluted 5-fold in PBS and applied for
1 h at room temperature. The secondary antibody (donkey anti-rabbit
Alexa568, catalog no. A10042; Invitrogen) was diluted (1:100) in the
same buffer and applied for 1 h at room temperature. Samples were mounted
with the antifade agent ProLong Gold with 4′,6-diamidino-2-phenylindole
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(DAPI) (ThermoFisher Scientific). Confocal imaging was performed with the
Olympus Fluoview 1000 laser scanning confocal microscope using a 60× oil
immersion objective lens with numerical aperture 1.42. Z-stack images were
acquired with a step size of 0.3 μm and processed using the Fiji soft-
ware package (57). Cells expressing the different mutants were assessed for
the presence of clear filamentous structures and quantified in 2 to 5
independent experiments.
ACKNOWLEDGMENTS. We thank M. Hansch, I. Hammerl-Witzel, and J. Hu
for technical assistance. We also thank J. Gloeckner for providing us a plasmid
for the FSS (Flag-Strep-Strep)-tagged version of LRRK2 wt. This work was sup-
ported by Michael J. Fox Foundation Grant 11425 (https://www.michaeljfox.org/)
(to D.B., S.S.T., and F.W.H.), the Branfman Family Foundation (D.B. and M.H.E.),
National Institute of General Medical Sciences Grant P41GM103412 (to M.H.E.),
and Future (PhosMOrg) of Kassel University (F.W.H.).
1. C. J. Gloeckner et al., The Parkinson disease causing LRRK2 mutation I2020T is asso-
ciated with increased kinase activity. Hum. Mol. Genet. 15, 223–232 (2006).
2. S. Ray et al., The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an
active state conformation leading to increased kinase activity. J. Biol. Chem. 289,
13042–13053 (2014).
3. M. K. Lin, M. J. Farrer, Genetics and genomics of Parkinson’s disease. Genome Med. 6,
48 (2014).
4. E. K. Tan, L. M. Skipper, Pathogenic mutations in Parkinson disease. Hum. Mutat. 28,
641–653 (2007).
5. A. Zimprich et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with
pleomorphic pathology. Neuron 44, 601–607 (2004).
6. M. Funayama et al., A new locus for Parkinson’s disease (PARK8) maps to chromosome
12p11.2-q13.1. Ann. Neurol. 51, 296–301 (2002).
7. C. Paisán-Ruíz et al., Cloning of the gene containing mutations that cause PARK8-
linked Parkinson’s disease. Neuron 44, 595–600 (2004).
8. S. Dihanich et al., GTP binding controls complex formation by the human ROCO
protein MASL1. FEBS J. 281, 261–274 (2014).
9. L. Civiero, S. Dihanich, P. A. Lewis, E. Greggio, Genetic, structural, and molecular in-
sights into the function of ras of complex proteins domains. Chem. Biol. 21, 809–818
(2014).
10. Z. Berger, K. A. Smith, M. J. Lavoie, Membrane localization of LRRK2 is associated with
increased formation of the highly active LRRK2 dimer and changes in its phosphor-
ylation. Biochemistry 49, 5511–5523 (2010).
11. N. G. James et al., Number and brightness analysis of LRRK2 oligomerization in live
cells. Biophys. J. 102, L41–L43 (2012).
12. L. R. Kett et al., LRRK2 Parkinson disease mutations enhance its microtubule associ-
ation. Hum. Mol. Genet. 21, 890–899 (2012).
13. K. Muda et al., Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phos-
phorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc. Natl. Acad. Sci.
U.S.A. 111, E34–E43 (2014).
14. X. Li et al., Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by
common mutations of familial Parkinson’s disease. PLoS One 6, e17153 (2011).
15. N. Dzamko et al., Inhibition of LRRK2 kinase activity leads to dephosphorylation of
Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Biochem. J. 430, 405–413 (2010).
16. K. B. Fraser et al., LRRK2 secretion in exosomes is regulated by 14-3-3. Hum. Mol.
Genet. 22, 4988–5000 (2013).
17. L. Civiero et al., PAK6 phosphorylates 14-3-3γ to regulate steady state phosphoryla-
tion of LRRK2. Front. Mol. Neurosci. 10, 417 (2017).
18. H. J. Yun et al., An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J.
Biochem. 157, 485–495 (2015).
19. M. Steger et al., Phosphoproteomics reveals that Parkinson’s disease kinase
LRRK2 regulates a subset of Rab GTPases. eLife 5, e12813 (2016).
20. P. A. Eyers ‘Up with the LRRK’: A phosphorylated Rab10 assay for evaluation of
LRRK2 activity and inhibitor engagement. Biochem. J. 473, 2757–2762 (2016).
21. M. Yu et al., LRRK2 mediated Rab8a phosphorylation promotes lipid storage. Lipids
Health Dis. 17, 34 (2018).
22. E. Purlyte et al., Rab29 activation of the Parkinson’s disease-associated LRRK2 kinase.
EMBO J. 37, 1–18 (2018).
23. A. P. Kornev, N. M. Haste, S. S. Taylor, L. F. Eyck, Surface comparison of active and
inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad.
Sci. U.S.A. 103, 17783–17788 (2006).
24. A. P. Kornev, S. S. Taylor, L. F. Ten Eyck, A helix scaffold for the assembly of active
protein kinases. Proc. Natl. Acad. Sci. U.S.A. 105, 14377–14382 (2008).
25. A. P. Kornev, S. S. Taylor, Dynamics-driven allostery in protein kinases. Trends Bio-
chem. Sci. 40, 628–647 (2015).
26. J. Hu et al., Kinase regulation by hydrophobic spine assembly in cancer.Mol. Cell. Biol.
35, 264–276 (2015).
27. J. Hu et al., Allosteric activation of functionally asymmetric RAF kinase dimers. Cell
154, 1036–1046 (2013).
28. J. Hu et al., Mutation that blocks ATP binding creates a pseudokinase stabilizing the
scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci.
U.S.A. 108, 6067–6072 (2011).
29. J. Kim et al., A dynamic hydrophobic core orchestrates allostery in protein kinases. Sci.
Adv. 3, e1600663 (2017).
30. A. Torkamani, N. Kannan, S. S. Taylor, N. J. Schork, Congenital disease SNPs target
lineage specific structural elements in protein kinases. Proc. Natl. Acad. Sci. U.S.A. 105,
9011–9016 (2008).
31. H. S. Meharena et al., Deciphering the structural basis of eukaryotic protein kinase
regulation. PLoS Biol. 11, e1001680 (2013).
32. N. Kannan, A. F. Neuwald, Did protein kinase regulatory mechanisms evolve through
elaboration of a simple structural component? J. Mol. Biol. 351, 956–972 (2005).
33. G. Gosal, K. J. Kochut, N. Kannan, ProKinO: An ontology for integrative analysis of
protein kinases in cancer. PLoS One 6, e28782 (2011).
34. D. I. McSkimming et al., ProKinO: A unified resource for mining the cancer kinome.
Hum. Mutat. 36, 175–186 (2015).
35. L. A. Kelley, S. Mezulis, C. M. Yates, M. N. Wass, M. J. Sternberg, The Phyre2 web
portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845–858 (2015).
36. G. Guaitoli et al., Structural model of the dimeric Parkinson’s protein LRRK2 reveals a
compact architecture involving distant interdomain contacts. Proc. Natl. Acad. Sci.
U.S.A. 113, E4357–E4366 (2016).
37. H. S. Meharena et al., Decoding the interactions regulating the active state mechanics
of eukaryotic protein kinases. PLoS Biol. 14, e2000127 (2016).
38. M. Blanca Ramírez et al., GTP binding regulates cellular localization of Parkinson’s
disease-associated LRRK2. Hum. Mol. Genet. 26, 2747–2767 (2017).
39. A. J. Schwab, A. D. Ebert, Neurite aggregation and calcium dysfunction in iPSC-
derived sensory neurons with Parkinson’s disease-related LRRK2 G2019S mutation.
Stem Cell Reports 5, 1039–1052 (2015).
40. M. Hamm et al., Physiologically relevant factors influence tau phosphorylation by
leucine-rich repeat kinase 2. J. Neurosci. Res. 93, 1567–1580 (2015).
41. M. Caesar et al., Leucine-rich repeat kinase 2 functionally interacts with microtubules
and kinase-dependently modulates cell migration. Neurobiol. Dis. 54, 280–288 (2013).
42. F. Gillardon, Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms
and modulates microtubule stability–A point of convergence in parkinsonian neu-
rodegeneration? J. Neurochem. 110, 1514–1522 (2009).
43. M. J. Fell et al., MLi-2, a potent, selective, and centrally active compound for exploring
the therapeutic potential and safety of LRRK2 kinase inhibition. J. Pharmacol. Exp.
Ther. 355, 397–409 (2015).
44. M. Jaleel et al., LRRK2 phosphorylates moesin at threonine-558: Characterization of
how Parkinson’s disease mutants affect kinase activity. Biochem. J. 405, 307–317
(2007).
45. C. J. Gloeckner, A. Schumacher, K. Boldt, M. Ueffing, The Parkinson disease-associated
protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and
MKK4/7, in vitro. J. Neurochem. 109, 959–968 (2009).
46. E. Ohta, F. Kawakami, M. Kubo, F. Obata, LRRK2 directly phosphorylates Akt1 as a
possible physiological substrate: Impairment of the kinase activity by Parkinson’s
disease-associated mutations. FEBS Lett. 585, 2165–2170 (2011).
47. Z. Sheng et al., Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity
and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161
(2012).
48. E. Ohta et al., I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family
exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.
Hum. Mol. Genet. 24, 4879–4900 (2015).
49. A. F. Kalogeropulou et al., P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2)
substrate that enhances neuronal toxicity. Biochem. J. 475, 1271–1293 (2018).
50. A. S. Shaw, A. P. Kornev, J. Hu, L. G. Ahuja, S. S. Taylor, Kinases and pseudokinases:
Lessons from RAF. Mol. Cell. Biol. 34, 1538–1546 (2014).
51. M. Liu et al., Type II kinase inhibitors show an unexpected inhibition mode against
Parkinson’s disease-linked LRRK2 mutant G2019S. Biochemistry 52, 1725–1736 (2013).
52. C. Chen et al., Identification of a major determinant for serine-threonine kinase
phosphoacceptor specificity. Mol. Cell 53, 140–147 (2014).
53. C. L. McClendon, A. P. Kornev, M. K. Gilson, S. S. Taylor, Dynamic architecture of a
protein kinase. Proc. Natl. Acad. Sci. U.S.A. 111, E4623–E4631 (2014).
54. D. M. Jacobsen, Z. Q. Bao, P. O’Brien, C. L. Brooks, 3rd, M. A. Young, Price to be paid
for two-metal catalysis: Magnesium ions that accelerate chemistry unavoidably limit
product release from a protein kinase. J. Am. Chem. Soc. 134, 15357–15370 (2012).
55. Z. Q. Bao, D. M. Jacobsen, M. A. Young, Briefly bound to activate: Transient binding
of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase
for catalysis. Structure 19, 675–690 (2011).
56. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72,
248–254 (1976).
57. J. Schindelin et al., Fiji: An open-source platform for biological-image analysis. Nat.
Methods 9, 676–682 (2012).
14988 | www.pnas.org/cgi/doi/10.1073/pnas.1900289116 Schmidt et al.
